MTP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (25 Mar 2023 @ 03:59):

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally...

Stats
今日成交量	164 362
平均成交量	1.84M
市值	1.98M
EPS	$0 ( 2023-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.138
ATR14	$0.0550 (41.79%)

Insider Trading

Date	Person	Action	Amount	type
2011-05-10	Kiley Quinn Thomas	Buy	1 000	MLP & Strategic Equity Fund
2010-10-06	Zimmerman Gifford R	Buy	0
2010-10-06	Toth Terence J	Buy	0
2010-10-06	Schneider William J	Buy	0
2010-10-06	Martin Larry W	Buy	0

INSIDER POWER
0.00
Last 1 transactions
Buy: 1 000 \| Sell: 0

音量相关性

長: -0.24 (neutral)

短: -0.59 (weak negative)

Signal:(26.463) Neutral

Midatech Pharma PLC 相关性

10 最正相关
FWRD	0.961
GOVX	0.961
PETS	0.948
AGFY	0.947
RIDE	0.944
ENNV	0.944
CFRX	0.944
SOLO	0.941
MYMD	0.94
SINT	0.937

10 最负相关
TIOAU	-0.963
VLAT	-0.959
LDHA	-0.958
HORI	-0.956
APXI	-0.954
GEEX	-0.952
AGGR	-0.951
LEGA	-0.95
HCNE	-0.949
LVRA	-0.948

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Midatech Pharma PLC 相关性 - 货币/商品

-0.80
( moderate negative )

-0.46
( neutral )

0.00
( neutral )

-0.40
( neutral )

0.78
( moderate )

Midatech Pharma PLC 财务报表

Annual	2022
营收:	$699 000
毛利润:	$-4.41M (-631.19 %)
EPS:	$0

FY	2022
营收:	$699 000
毛利润:	$-4.41M (-631.19 %)
EPS:	$0

FY	2021
营收:	$578 000
毛利润:	$-4.08M (-705.19 %)
EPS:	$-1.695

FY	2020
营收:	$180 000
毛利润:	$-5.89M (-3 271.11 %)
EPS:	$-258.98

Financial Reports:

No articles found.

Midatech Pharma PLC

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.